• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dario Signs 6 New Employer Clients Representing Tens of Thousands of Lives Deepening its Leadership in Value-Based Care

    10/13/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care
    Get the next $DRIO alert in real time by email

    New clients span multiple industries and underscore broad increasing demand for Dario's multi-condition digital health platform

    Innovative new pricing model is highly attractive to prospective clients – supports Dario's continued market momentum and leading position as value-based solution provider

    NEW YORK, Oct. 13, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the addition of six (6) new employer clients to its growing portfolio, underscoring accelerating demand for integrated, multi-condition digital health solutions that improve health and reduce costs, as well as the deployment of a new pricing model that deepens the Company's value-based care strategy. This value-based pricing framework ties payments directly to member engagement and clinical progress – a structure that aims to help clients navigate costs by leveraging Dario's industry leading platform that delivers 5X return on investment ("ROI") and approximately $5,000 annual saving per Dario user. 

     

    DarioHealth Logo

     

    The newly added employers span multiple sectors, including manufacturing, education, advertising, and professional services, representing tens of thousands of newly covered employees nationwide. Organizations include a multinational building materials manufacturer with more than 6,000 U.S.-based employees, a national education nonprofit providing curriculum and professional development support to thousands of educators, a global advertising and media conglomerate with a strong U.S. employee base, and one of the largest public-school districts in the U.S., employing more than 40,000 teachers and staff.

    Agreements with 3 of the 6 new clients utilize a milestone-based framework that ties payments directly to member engagement and clinical progress. This results-focused model makes it significantly easier for clients to align costs, in-year, with real clinical outcomes, and facilitates their ongoing transition to value-based care – without adding burdensome administrative complexity.

    Uniquely positioned in the digital health industry to deliver value-based care, Dario has 92 peer reviewed studies, more than any other company in the industry, demonstrating improved health outcomes and reduced spending. Dario's value-based pricing can deliver improved economics for its clients while further accelerating the Company's market penetration.

    These new clients chose Dario in order to provide digital health support to employees across multiple chronic conditions, including cardiometabolic (diabetes, hypertension, weight management), musculoskeletal and behavioral health, all supported by the Company's AI-enabled platform.

    "Employers are increasingly looking for solutions that consolidate care, engage employees and demonstrate clear ROI on healthcare spend," said Steven Nelson, Dario's President and Chief Commercial Officer. "The addition of 6 new clients across such diverse industries is a strong signal that the market continues to move broadly toward integrated, multi-condition solutions like Dario's. We believe further that our value-based care structure demonstrates that Dario is not just ready for the future of digital health – we are helping to shape it, with a simple but powerful model helping clients scale value-based care while driving measurable outcomes."

    Addressing Employer Needs in a Challenging Market

    U.S. employers continue to battle rising healthcare expenses, particularly related to chronic conditions, which account for significant productivity losses and billions of dollars in claims costs, according to the Centers for Disease Control and Prevention ("CDC"). By integrating multiple condition areas into a single, comprehensive digital health platform, Dario provides a significantly more cost-effective, high-engagement alternative to single-point solutions. Clients pay just one price on a single contract for a platform that is easy to use and simple to implement with the average member using 2.4 programs. The immediate additional savings that come through consolidating multiple vendors into one, combined with the proven clinical improvements driven by the solution, generate an industry-leading ROI while eliminating headaches and costly overhead for clients. 

    These six new employer contracts build on Dario's momentum in the employer market, adding to a client roster that already includes leading insurers, employers, pharma companies and strategic partners.

    About DarioHealth Corp.

    DarioHealth Corp. (NASDAQ:DRIO) is a leading digital health company revolutionizing how people with chronic conditions manage their health through a user-centric, multi-chronic condition digital therapeutics platform. Dario's platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain and behavioral health.

    Dario's user-centric platform offers people continuous and customized care for their health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention and results and making the right thing to do the easy thing to do.

    Dario provides its highly user-rated solutions globally to health plans and other payers, self-insured employers, providers of care and consumers. To learn more about Dario and its digital health solutions, or for more information, visit http://dariohealth.com. 

    Cautionary Note Regarding Forward-Looking Statements

    This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the Company's continued market momentum and leading position as a value-based solution provider; the Company's value-based pricing framework will help clients navigate costs by leveraging the Company's platform that delivers 5X ROI and approximately $5,000 annual saving per user; the future benefits of the Company's new pricing model; the belief that the market will continue to move toward integrated, multi-condition solutions like the Company's solutions; and the future benefits of the Company's solutions to clients. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

    Logo: https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

    DarioHealth Corporate Contacts

    Michael Lipari

    SVP Corporate Development

    [email protected]

    +1-201-785-6310

    Rob Halpern

    SVP Marketing

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/dario-signs-6-new-employer-clients-representing-tens-of-thousands-of-lives-deepening-its-leadership-in-value-based-care-302581984.html

    SOURCE DarioHealth Corp.

    Get the next $DRIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DRIO

    DatePrice TargetRatingAnalyst
    1/29/2025$2.00 → $1.00Buy → Hold
    TD Cowen
    5/13/2022$8.75Neutral → Buy
    Alliance Global Partners
    1/26/2022$28.00 → $25.00Buy
    Aegis Capital
    8/19/2021$35.00 → $28.00Buy
    Aegis Capital
    More analyst ratings

    $DRIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DarioHealth downgraded by TD Cowen with a new price target

    TD Cowen downgraded DarioHealth from Buy to Hold and set a new price target of $1.00 from $2.00 previously

    1/29/25 7:36:04 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth upgraded by Alliance Global Partners with a new price target

    Alliance Global Partners upgraded DarioHealth from Neutral to Buy and set a new price target of $8.75

    5/13/22 9:01:42 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Aegis Capital reiterated coverage on DarioHealth with a new price target

    Aegis Capital reiterated coverage of DarioHealth with a rating of Buy and set a new price target of $25.00 from $28.00 previously

    1/26/22 10:35:44 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dario Signs 6 New Employer Clients Representing Tens of Thousands of Lives Deepening its Leadership in Value-Based Care

    New clients span multiple industries and underscore broad increasing demand for Dario's multi-condition digital health platform Innovative new pricing model is highly attractive to prospective clients – supports Dario's continued market momentum and leading position as value-based solution provider NEW YORK, Oct. 13, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced the addition of six (6) new employer clients to its growing portfolio, underscoring accelerating demand for integrated, multi-condition digital health solutions that improve health and reduce costs, as well as the deployment of a new pri

    10/13/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth and OneStep Announce Strategic Collaboration to Integrate Smartphone-Only, Clinical-Grade Fall Risk Assessment Technology into Dario's Digital Health Multi-Condition Platform

    Collaboration designed to drive measurable return on investment ("ROI") for health plans by reducing falls and improving outcomes for high-risk populations, including those with obesity and Medicare Advantage members with frailty and balance issues Generating more than $50 billion annually in direct medical costs, falls are one of the leading causes of injury among older adults in the U.S. NEW YORK, Oct. 6, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, and OneStep, the U.S. Food and Drug Administration ("FDA")-listed platform that delivers clinical-grade gait and mobility insights using only a smartphone, today

    10/6/25 7:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Announces Strategic Review Following Multiple Unsolicited Inbound Expressions of Interest

    Board forms Special Committee and engages Perella Weinberg Partners as financial advisor Company completed an oversubscribed $17.5 million private placement to capitalize on significant commercial momentum Dario optimized its cap table by converting preferred shares into common shares and common shares equivalents, positioning it for future opportunities NEW YORK, Sept. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leader in digital health solutions for chronic condition management, today announced that its Board of Directors has initiated a comprehensive strategic review to maximize shareholder value following multiple unsolicited inbound strategic

    9/25/25 6:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles was granted 30,000 shares, increasing direct ownership by 632% to 34,750 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:04:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Stern Adam K was granted 20,000 shares, increasing direct ownership by 206% to 29,717 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 6:03:10 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Director Leisure Lawrence B. was granted 20,000 shares (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/15/25 4:20:39 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CCO Nelson Steven Charles bought $21,200 worth of shares (40,000 units at $0.53), increasing direct ownership by 73% to 95,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    8/27/25 4:30:59 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $4,546 worth of shares (5,000 units at $0.91), increasing direct ownership by 10% to 55,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    11/14/24 4:15:15 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Nelson Steven Charles bought $8,244 worth of shares (10,000 units at $0.82), increasing direct ownership by 25% to 50,000 units (SEC Form 4)

    4 - DarioHealth Corp. (0001533998) (Issuer)

    9/12/24 4:37:42 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    SEC Filings

    View All

    SEC Form D filed by DarioHealth Corp.

    D - DarioHealth Corp. (0001533998) (Filer)

    10/7/25 4:01:08 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    9/25/25 5:18:21 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Corp. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - DarioHealth Corp. (0001533998) (Filer)

    9/19/25 5:01:09 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Leadership Updates

    Live Leadership Updates

    View All

    DarioHealth Appoints Healthcare Industry Leader Larry Leisure to Board of Directors

    Healthcare innovator and former Accenture executive brings deep industry relationships to advance Dario's AI-driven chronic care platform. NEW YORK, Feb. 27, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in AI-driven digital health solutions, today announced the appointment of Lawrence (Larry) B. Leisure to its Board of Directors, bringing four decades of healthcare leadership, managed care expertise, and digital health innovation to the company's governance. Mr. Leisure's extensive experience working with health plans, health systems, consultants, and employer coalitions, combined with his deep understanding of health policy, reimbursement, and va

    2/27/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

    Concurrently, the Company accepted the resignations of Dr. Colin Goddard and Mr. Joacim Borg OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate biopharmaceutical company, today announced the appointments of Avril McKean Dieser, MA, JD and Olivier R. Jarry, MS, MBA as independent members of the Company's Board of Directors. Collectively, Ms. McKean Dieser and Mr. Jarry bring over 50 years of biopharmaceutical executive decision-making experience to the Company, with a specific focus in commercializing biologic products. "OS Therapies is thrilled to welcome Ms. McKean Dieser and Mr. Jarry to our Board of Directors," sa

    10/28/24 4:44:00 PM ET
    $BMY
    $DRIO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Empowering Commercial Expansion: DarioHealth Announces Strategic Reorganization and Appoints Inaugural Chief Commercial Officer

    After two decades of successfully scaling multiple healthcare companies, Steven Nelson joins DarioHealth as Chief Commercial Officer to accelerate revenue growth across the health plans, employers and pharma channels NEW YORK, June 5, 2024 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario", "DarioHealth" or the "Company"), a leader in the global digital health market, announced today a strategic reorganization designed to streamline leadership and focus the organization on accelerating its commercialization efforts. This move reflects the Company's commitment to bringing its innovative solutions to the market faster, maximizing customer impact, and driving the organization to profitabi

    6/5/24 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Financials

    Live finance-specific insights

    View All

    DarioHealth Announces 20-to-1 Reverse Stock Split

    NEW YORK, Aug. 25, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, today announced that a reverse stock split of the Company's issued and outstanding common stock, par value $0.0001 per share (the "Common Stock") at a ratio of 20-for-1 is expected to be implemented at market open on August 28, 2025. The Company's Common Stock will begin trading on the Nasdaq Capital Market on a post-split basis at the market open on August 28, 2025, under the Company's existing trading symbol "DRIO", but will trade under a new CUSIP Number, 23725P 308. After giving effect to the reverse share split of the Company's Common Stock,

    8/25/25 8:00:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth Reports Second Quarter 2025 Financial and Operating Results

    Second quarter 2025 revenue was $5.4 million, compared to $6.3 million in the second quarter of 2024, and $6.8 million in the first quarter of 2025 - The Company believes that strong client momentum and strategic wins will offset decrease in revenues Approximately $5 million new committed annual recurring revenues ("CARR"); Plus $53 million pipeline of commercial opportunities, over $5 million of which is in final stages toward CARR - On track to secure total of 40 new clients by the end of 2025 Two new health plan clients are expected to represent multi-million-dollar opportunities for Dario over time, including a full-suite national health plan scheduled to launch in the second half of 20

    8/12/25 6:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    DarioHealth to Report Second Quarter 2025 Results on Tuesday, August 12, 2025

    Company to host conference call and webcast at 8:30 a.m. Eastern Time NEW YORK, Aug. 5, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ:DRIO) ("Dario" or the "Company"), a leader in the global digital health market, announced today that it will release its financial results for the 2nd quarter ended June 30th, 2025 and will host a conference call and webcast at 8:30 a.m. Eastern Time, on Tuesday, August 12th, 2025, before the market opens. Erez Raphael, Chief Executive Officer, Steven Nelson, President and Chief Commercial Officer, and Chen Franco-Yehuda, Chief Financial Officer, will host the call. Conference Call Details Date: Tuesday, August 12th, 2025, 8:30 a.m. Eastern Time Dial-in Numb

    8/5/25 8:30:00 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    $DRIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    12/13/24 4:05:12 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by DarioHealth Corp.

    SC 13G - DarioHealth Corp. (0001533998) (Subject)

    10/29/24 11:45:28 AM ET
    $DRIO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by DarioHealth Corp. (Amendment)

    SC 13G/A - DarioHealth Corp. (0001533998) (Subject)

    2/14/24 4:51:40 PM ET
    $DRIO
    Medical/Dental Instruments
    Health Care